肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

赛诺菲宣布将以25亿美元收购Synthorx，以增强其肿瘤免疫学业务

2019-12-16 不详 MedSci原创

赛诺菲25亿美元SynthorxIL-2肿瘤免疫学
关注

赛诺菲与Synthorx已达成最终协议，根据该协议，赛诺菲将以每股68美元的现金收购Synthorx的所有流通股，相当于总股本价值约25亿美元（按完全稀释后的价值）。

赛诺菲与Synthorx已达成最终协议，根据该协议，赛诺菲将以每股68美元的现金收购Synthorx的所有流通股，相当于总股本价值约25亿美元（按完全稀释后的价值）。

赛诺菲首席执行官Paul Hudson表示："此次收购完全符合我们建立优质资产组合并引领创新的战略。"

Synthorx的主要肿瘤免疫候选产品THOR-707是白细胞介素2（IL-2）的变体，目前正在多种实体瘤的临床开发中作为单一药物或与免疫检查点抑制剂联用。据报道，与其他IL-2药物相比，它有可能成为治疗实体瘤的同类最佳IL-2治疗剂，并显示出改善的药理学、较低的给药频率和疗效。

该公司表示，在赛诺菲的产品线中增加THOR-707和Synthorx的其他早期细胞因子计划将提高赛诺菲在肿瘤学和肿瘤免疫学领域的地位。

赛诺菲曾表示，预计将在2020年第一季度完成收购。

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1889426, encodeId=7483188942615, content=<a href='/topic/show?id=f9fa290030a' target=_blank style='color:#2F92EE;'>#免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29003, encryptionId=f9fa290030a, topicName=免疫学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Wed Sep 02 16:10:00 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795230, encodeId=b8a61e9523008, content=<a href='/topic/show?id=52af1699ebc' target=_blank style='color:#2F92EE;'>#Synthorx#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16997, encryptionId=52af1699ebc, topicName=Synthorx)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Dec 27 18:10:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618191, encodeId=48a8161819116, content=<a href='/topic/show?id=9e0d8281054' target=_blank style='color:#2F92EE;'>#肿瘤免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82810, encryptionId=9e0d8281054, topicName=肿瘤免疫学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8dd19859628, createdName=12498cbcm06(暂无昵称), createdTime=Wed Dec 18 01:10:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377058, encodeId=1c233e7058fd, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Dec 17 07:15:30 CST 2019, time=2019-12-17, status=1, ipAttribution=)]
    2020-09-02 xiaoyeshuang

    #免疫学#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1889426, encodeId=7483188942615, content=<a href='/topic/show?id=f9fa290030a' target=_blank style='color:#2F92EE;'>#免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29003, encryptionId=f9fa290030a, topicName=免疫学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Wed Sep 02 16:10:00 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795230, encodeId=b8a61e9523008, content=<a href='/topic/show?id=52af1699ebc' target=_blank style='color:#2F92EE;'>#Synthorx#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16997, encryptionId=52af1699ebc, topicName=Synthorx)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Dec 27 18:10:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618191, encodeId=48a8161819116, content=<a href='/topic/show?id=9e0d8281054' target=_blank style='color:#2F92EE;'>#肿瘤免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82810, encryptionId=9e0d8281054, topicName=肿瘤免疫学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8dd19859628, createdName=12498cbcm06(暂无昵称), createdTime=Wed Dec 18 01:10:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377058, encodeId=1c233e7058fd, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Dec 17 07:15:30 CST 2019, time=2019-12-17, status=1, ipAttribution=)]
    2019-12-27 jambiya

    #Synthorx#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1889426, encodeId=7483188942615, content=<a href='/topic/show?id=f9fa290030a' target=_blank style='color:#2F92EE;'>#免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29003, encryptionId=f9fa290030a, topicName=免疫学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Wed Sep 02 16:10:00 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795230, encodeId=b8a61e9523008, content=<a href='/topic/show?id=52af1699ebc' target=_blank style='color:#2F92EE;'>#Synthorx#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16997, encryptionId=52af1699ebc, topicName=Synthorx)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Dec 27 18:10:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618191, encodeId=48a8161819116, content=<a href='/topic/show?id=9e0d8281054' target=_blank style='color:#2F92EE;'>#肿瘤免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82810, encryptionId=9e0d8281054, topicName=肿瘤免疫学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8dd19859628, createdName=12498cbcm06(暂无昵称), createdTime=Wed Dec 18 01:10:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377058, encodeId=1c233e7058fd, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Dec 17 07:15:30 CST 2019, time=2019-12-17, status=1, ipAttribution=)]
    2019-12-18 12498cbcm06(暂无昵称)

    #肿瘤免疫学#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1889426, encodeId=7483188942615, content=<a href='/topic/show?id=f9fa290030a' target=_blank style='color:#2F92EE;'>#免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29003, encryptionId=f9fa290030a, topicName=免疫学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Wed Sep 02 16:10:00 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795230, encodeId=b8a61e9523008, content=<a href='/topic/show?id=52af1699ebc' target=_blank style='color:#2F92EE;'>#Synthorx#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16997, encryptionId=52af1699ebc, topicName=Synthorx)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Dec 27 18:10:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618191, encodeId=48a8161819116, content=<a href='/topic/show?id=9e0d8281054' target=_blank style='color:#2F92EE;'>#肿瘤免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82810, encryptionId=9e0d8281054, topicName=肿瘤免疫学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8dd19859628, createdName=12498cbcm06(暂无昵称), createdTime=Wed Dec 18 01:10:00 CST 2019, time=2019-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377058, encodeId=1c233e7058fd, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbc11488193, createdName=thm112988, createdTime=Tue Dec 17 07:15:30 CST 2019, time=2019-12-17, status=1, ipAttribution=)]
    2019-12-17 thm112988

    好

    0

相关资讯

赛诺菲公布其长效胰岛素Toujeo治疗青少年糖尿病的3期阳性结果

法国制药商赛诺菲（Sanofi）公开了其长效胰岛素Toujeo（甘精胰岛素300单位/ mL）的积极结果，并将其与Lantus（甘精胰岛素100单位/ mL）进行比较，后者在去年失去了专利。EDITION JUNIOR研究评估了Toujeo在6-17岁的1型糖尿病（T1D）儿童和青少年的药效。

全球特应性皮炎靶向生物制剂Dupixent® 亮相进博会

长久以来，我国中重度特应性皮炎患者一直饱受剧烈瘙痒和大面积皮损的折磨，缺乏安全有效的治疗方案，严重影响着工作和生活。随着第二届中国国际进口博览会的召开，被疾病纠缠的他们也迎来了最前沿的创新性治疗方案——全球首个也是目前唯一获得美国食品药品监督管理局（FDA）及欧盟批准的治疗成人中重度特应性皮炎的靶向生物制剂Dupixent®（Dupilumab），可显著、持久地改善特应性皮炎患者的皮损程度和瘙痒症

终止与Lexicon合作，重磅产品销售下滑赛诺菲糖尿病业务靠谁崛起？

近日，Lexicon 与赛诺菲正式终止了Zynquista (sotagliflozin) 的开发和商业化合作协议，该合作协议签订于2015年11月，首付款+里程碑金高达17亿美元。

赛诺菲携3款罕见病新药亮相进博会: 为法布雷病、血友病及黏多糖贮积症患者带来新希望

2019年11月6日 ，全世界已知的罕见病约有7000种，但其中只有约6%的疾病有药可治。“去世前，希望能够用上一次药”是很多罕见病患者短暂生命中的唯一期盼。作为罕见病治疗领域的先行者和领导者，赛诺菲在第二届中国国际进口博览会上带来了三款罕见病领域的创新药物，以期助力中国法布雷病、B型血友病及黏多糖贮积症Ⅰ型患者直面健康挑战，绽放生命的希望。先行探索，积极推动罕见病药物可及性罕见病，又称孤儿病，是

赛诺菲宣布自愿在美国和欧洲召回污染了亚硝胺二甲胺的雷尼替丁

赛诺菲已宣布在美国和加拿大自愿召回Zantac（雷尼替丁）非处方药（OTC），主要原因是由于该药物中可能污染了亚硝胺二甲胺（NDMA）（一种可能的人类致癌物）的杂质。

白细胞介素4/13单抗Dupixent销售额持续增长，但未能扭转赛诺菲因流感疫苗和糖尿病药物导致的整体销售额下降

赛诺菲（Sanofi）报告第三季度销售额下降，原因是其免疫学药物Dupixent的销售额增加无法抵消其疫苗和初级保健业务的下跌。Dupixent是一种全人源化单克隆抗体，特异性抑制两种炎症因子白细胞介素IL-4和IL-13的过度激活，而这两种炎症因子是特应性皮炎、哮喘和嗜酸细胞性食管炎等关键的驱动因素。